3sbio (1530.HK) stock price, revenue, and financials

3sbio market cap is $15.8 b, and annual revenue was ¥6.38 b in FY 2021

$15.8 B

1530.HK Mkt cap, 07-Jun-2022

¥6.4 B

3sbio Revenue FY, 2021
3sbio Gross profit (FY, 2021)5.7 B
3sbio Net income (FY, 2021)1.6 B
3sbio EBITDA (FY, 2021)2.2 B
3sbio EBIT (FY, 2021)1.8 B
3sbio Cash, 31-Dec-20212.9 B
3sbio EV15.6 B
Get notified regarding key financial metrics and revenue changes at 3sbioLearn more
Banner background

3sbio Revenue Breakdown

Embed Graph

3sbio revenue breakdown by business segment: 100.0% from PHARMACEUTICAL DIVERSIFIED

3sbio Income Statement

Annual

CNYFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

4.6b5.3b5.6b6.4b

Cost of goods sold

(564.0m)(591.4m)(702.0m)(777.3m)

Gross profit

4.1b4.8b5.0b5.7b

R&D expense

(362.7m)(526.6m)(590.3m)(753.9m)

Operating expense total

(2.4b)(3.2b)(3.2b)(3.5b)

Depreciation and amortization

(313.3m)(334.0m)(538.7m)(329.0m)

EBITDA

1.7b1.6b1.8b2.2b

EBIT

1.3b1.2b1.2b1.8b

Interest expense

(138.4m)(109.5m)(81.1m)(66.5m)

Interest income

64.8m83.9m84.5m98.7m

Pre tax profit

1.5b1.2b979.1m1.9b

Income tax expense

(218.3m)(242.8m)(208.0m)(241.2m)

Net Income

1.3b980.2m771.1m1.6b

Half Year

CNYH1, 2019H1, 2020H1, 2021

Revenue

2.6b2.7b3.1b

Cost of goods sold

(292.6m)(303.6m)(360.3m)

Gross profit

2.4b2.4b2.8b

R&D expense

(263.9m)(254.3m)(344.9m)

Operating expense total

(1.8b)(1.4b)(1.7b)

Depreciation and amortization

(165.8m)(174.5m)(159.7m)

EBITDA

619.7m1.0b1.1b

EBIT

417.7m820.6m946.0m

Interest expense

(48.2m)(43.6m)(32.3m)

Interest income

32.9m36.8m46.1m

Pre tax profit

406.6m818.6m1.0b

Income tax expense

(95.4m)(132.8m)(134.8m)

Net Income

311.2m685.7m891.0m

3sbio Balance Sheet

Annual

CNYFY, 2018FY, 2019FY, 2020FY, 2021

Cash

1.8b2.1b3.1b2.9b

Accounts Receivable

1.3b930.8m860.0m1.3b

Prepaid Expenses

45.1m49.1m112.7m233.3m

Inventories

384.6m528.5m619.5m690.5m

Current Assets

4.4b4.6b6.7b7.8b

PP&E

1.8b2.0b2.6b3.4b

Goodwill

4.1b4.1b3.9b3.8b

Total Assets

13.8b14.8b17.7b19.2b

Accounts Payable

112.9m149.8m203.3m230.4m

Short-term debt

570.3m489.4m367.2m160.8m

Current Liabilities

1.7b1.6b1.5b1.4b

Long-term debt

2.7b2.3b2.5b2.5b

Non-Current Liabilities

3.3b2.8b3.1b3.1b

Total Debt

3.3b2.8b2.9b2.6b

Total Liabilities

4.9b4.4b4.6b4.6b

Common Stock

156.0k155.0k155.0k155.0k

Additional Paid-in Capital

4.4b4.3b4.3b4.2b

Retained Earnings

3.5b4.3b5.0b6.6b

Total Equity

8.9b10.4b13.1b14.7b

Half Year

CNYH1, 2019H1, 2020H1, 2021

Cash

1.4b3.8b2.9b

Accounts Receivable

1.5b1.1b1.2b

Prepaid Expenses

756.4m504.8m582.7m

Inventories

449.8m569.9m681.5m

Current Assets

5.1b6.9b7.4b

PP&E

1.8b2.1b3.0b

Goodwill

4.1b4.2b3.9b

Total Assets

14.9b17.6b18.5b

Accounts Payable

170.7m166.2m214.9m

Short-term debt

1.2b467.5m159.4m

Current Liabilities

2.4b1.7b1.3b

Long-term debt

2.4b3.9b2.5b

Non-Current Liabilities

3.0b4.5b3.1b

Total Debt

3.6b4.4b2.6b

Total Liabilities

5.3b6.1b4.4b

Common Stock

155.0k155.0k156.0k

Additional Paid-in Capital

4.3b4.3b4.3b

Retained Earnings

3.7b4.9b6.0b

Total Equity

9.6b11.5b14.1b

3sbio Cash Flow

Annual

CNYFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

1.5b1.2b979.1m1.9b

Depreciation and Amortization

313.3m320.7m342.1m306.4m

Accounts Receivable

(264.5m)453.9m34.9m(401.2m)

Inventories

(35.7m)(124.9m)(93.1m)(67.1m)

Accounts Payable

(51.8m)37.0m53.2m27.1m

Cash From Operating Activities

1.2b1.9b1.3b1.6b

Cash From Investing Activities

(405.9m)(1.1b)(1.9b)(1.3b)

Long-term Borrowings

(1.2b)(510.5m)(87.6m)(93.8m)

Dividends Paid

(150.8m)(16.3m)

Cash From Financing Activities

(1.4b)(454.4m)1.6b(481.1m)

Net Change in Cash

(606.0m)290.2m1.0b(222.8m)

Half Year

CNYH1, 2019H1, 2020H1, 2021

Net Income

406.6m818.6m1.0b

Depreciation and Amortization

164.1m167.0m149.0m

Accounts Receivable

(75.5m)(167.5m)(245.1m)

Inventories

(66.1m)(37.3m)(57.1m)

Accounts Payable

57.4m16.4m11.7m

Cash From Operating Activities

699.6m708.2m811.5m

Cash From Investing Activities

(1.4b)(657.5m)(766.0m)

Long-term Borrowings

324.3m(27.4m)(197.7m)

Cash From Financing Activities

321.9m1.6b(202.9m)

Net Change in Cash

(412.7m)1.7b(171.2m)

3sbio Ratios

CNYFY, 2018